Patients remain sidelined in this scheme, as their cost-sharing is based on the list price, not the discounted rate. PBMs have become powerful gatekeepers in the prescription drug market ...
For years, these cities and states have insisted on a cut—if not all—of the rebates that these pharmacybenefit managers ... make two claims: that insulinprices are unreasonably high and ...
The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to ...
Results that may be inaccessible to you are currently showing.